Article
Ventana and MedImmune to Develop a PD-L1 Assay To Aid Patient Enrollment in Immunotherapy Trials
Ventana Medical Systems, Inc. and MedImmune today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.
MEDI4736 is an investigational, engineered, human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. It is believed that by targeting PD-L1, MEDI4736 may block this ligand from sending out signals to T-cells to 'ignore' tumor cells, thereby countering cancer's immune-evading tactics.
The PD-L1 Investigational Use Only (IUO) assay in development that is supporting MEDI4736 clinical trials- is based on a SP263 (Spring Bioscience) rabbit monoclonal antibody.
"Cancer immunotherapy is a promising area that may provide long lasting benefit not achieved with other treatment approaches. This collaboration is another strong example of the importance of companion diagnostics and their role in supporting the use of novel immunotherapies to target human malignancies," says Doug Ward, VP and Lifecycle Leader for the Ventana Companion Diagnostics business unit. "We're proud to provide high quality reagents like SP263 to support MedImmune's immunotherapy development efforts to advance the standard of care for cancer patients."
Read the report here: http://on.mktw.net/1uZDiqd
Source: MarketWatch
